Education
About Us
Working with TipRanks
Follow Us
Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
Total Valuation
Monte Rosa Therapeutics has a market cap or net worth of $1.25B. The enterprise value is $896.58M.
Market Cap$1.25B
Enterprise Value$896.58M
Share Statistics
Monte Rosa Therapeutics has 76,242,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding76,242,760
Owned by Insiders10.95%
Owned by Institutions10.70%
Financial Efficiency
Monte Rosa Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee870.93K
Profits Per Employee-272.01K
Employee Count142
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Monte Rosa Therapeutics is ―. Monte Rosa Therapeutics’s PEG ratio is -0.05.
PE Ratio―
PS Ratio47.82
PB Ratio2.48
Price to Fair Value―
Price to FCF6.12
Price to Operating Cash Flow9.03
PEG Ratio-0.05
Income Statement
In the last 12 months, Monte Rosa Therapeutics had revenue of 123.67M and earned -38.63M in profits. Earnings per share was 0.00.
Revenue123.67M
Gross Profit0.00
Operating Income-54.21M
Pretax Income-39.72M
Net Income-38.63M
EBITDA-54.21M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was 149.14M and capital expenditures -4.12M, giving a free cash flow of 145.02M billion.
Operating Cash Flow149.14M
Free Cash Flow145.02M
Free Cash Flow per Share1.90
Dividends & Yields
Monte Rosa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.78
52-Week Price Change145.13%
50-Day Moving Average19.89
200-Day Moving Average11.50
Relative Strength Index (RSI)36.13
Average Volume (3m)947.67K
Important Dates
Monte Rosa Therapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 17, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Monte Rosa Therapeutics as a current ratio of ―, with Debt / Equity ratio of 16.34%
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Monte Rosa Therapeutics has paid 1.10M in taxes.
Income Tax1.10M
Effective Tax Rate―
Enterprise Valuation
Monte Rosa Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Monte Rosa Therapeutics has $391.26M in cash and marketable securities with $40.17M in debt, giving a net cash position of $351.09M billion.
Cash & Marketable Securities$391.26M
Total Debt$40.17M
Net Cash$351.09M
Net Cash Per Share$4.60
Tangible Book Value Per Share―
Margins
Gross margin is 98.85%, with operating margin of ―, and net profit margin of ―.
Gross Margin98.85%
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Monte Rosa Therapeutics is $33.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$33.80
Price Target Upside106.73% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast1112.27%
EPS Growth Forecast―